세계의 산후 우울증 시장 보고서(2025년)
Postpartum Depression Global Market Report 2025
상품코드 : 1825516
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,448,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,320,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,193,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

산후 우울증 시장 규모는 향후 수년간 비약적인 성장이 전망됩니다. 2029년에는 CAGR 32.5%로 494억 9,000만 달러로 성장합니다. 예측 기간의 성장은 원격의료 서비스, 약리학의 발전, 임산부 정신건강에 관한 법률, 정신건강 종사자의 확대에 기인합니다. 예측 기간의 주요 동향으로는 통합 케어 모델, 동료 지원 프로그램, 주산기 정신건강 앱, 정신건강 스크리닝 툴 등이 있습니다.

향후 5년간 성장률 32.5%라는 예측은 지난번 예측보다 0.1% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 무역 마찰로 인해 스위스에서 개발된 브렉사놀론 정맥주사제의 가격이 급등하고, 임산부의 정신건강 개입이 지연되고, 정신과 의료비가 상승하여 미국내 속효성 신경스테로이드 요법의 채택을 저해할 수 있습니다. 또한 상호 관세와 무역 긴장과 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

산후우울증 사례 증가는 산후우울증 시장의 성장을 가속할 것으로 예측됩니다. 산후우울증은 출산 후 발생하는 과도한 걱정과 정신적 고통을 말하며, 종종 신체적 증상을 동반합니다. 산후우울증은 산후우울증이나 불안증과 동반되는 것이 일반적이며, 증상은 산후 1년 중 어느 시점부터 시작될 수 있습니다. 산후우울증 치료법에는 정신치료, 약물 치료 또는 이 두 가지의 조합으로 알려진 대화치료나 정신건강 상담이 있으며, 이는 시장 성장에 기여하고 있습니다. 예를 들어 버지니아대학교 의과대학(UVA SoM)이 2022년 2월 110만 명의 산모를 대상으로 실시한 조사에 따르면 초산부, 25세 미만, 쌍둥이 엄마가 산후 우울증의 위험이 가장 높은 것으로 나타났습니다. 연령대별로는 18-24세 여성의 산후우울증 자가보고율이 10%로 가장 높았습니다. 쌍둥이 어머니는 외동딸 어머니(8.3%)에 비해 증상의 비율이 높았다(11.3%). 이처럼 산후우울증 유병률 증가는 산후우울증 시장의 성장을 가속할 것입니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 대기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 합병과 인수

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSA
영문 목차

영문목차

Postpartum depression (PPD) is a mood disorder that affects some women after giving birth and often goes undiagnosed for extended periods. It is characterized by feelings of sadness, hopelessness, and a loss of interest or pleasure in activities once enjoyed.

The main types of postpartum depression include postpartum blues, postpartum anxiety, postpartum obsessive-compulsive disorder, postpartum panic disorder, postpartum post-traumatic stress disorder, postpartum psychosis, and others. Postpartum blues is a common but self-limiting condition that occurs shortly after childbirth, featuring symptoms such as mood swings, irritability, and tearfulness. Treatment for postpartum depression involves various approaches, including psychotherapy, medication, supplements, and other therapeutic interventions. These treatments can be administered in different ways, such as orally, through injections, and more. Postpartum depression remedies are available through various distribution channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others. They are used by a range of end-users, including hospitals, specialty clinics, home-care settings, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The postpartum depression market research report is one of a series of new reports from The Business Research Company that provides postpartum depression market statistics, including postpartum depression industry global market size, regional shares, competitors with a postpartum depression market share, detailed postpartum depression market segments, market trends and opportunities and any further data you may need to thrive in the postpartum depression industry. This postpartum depression market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The postpartum depression market size has grown exponentially in recent years. It will grow from $12.15 billion in 2024 to $16.05 billion in 2025 at a compound annual growth rate (CAGR) of 32.1%. The growth in the historic period can be attributed to maternal mental health awareness, research advancements, public health initiatives, increased screenings.

The postpartum depression market size is expected to see exponential growth in the next few years. It will grow to $49.49 billion in 2029 at a compound annual growth rate (CAGR) of 32.5%. The growth in the forecast period can be attributed to telehealth services, pharmacological advancements, maternal mental health legislation, mental health workforce expansion. Major trends in the forecast period include integrated care models, peer support programs, perinatal mental health apps, mental health screening tools.

The forecast of 32.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of rapid-acting neurosteroid therapies by inflating prices of brexanolone IV formulations developed in Switzerland, resulting in delayed maternal mental health interventions and higher psychiatric care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

An increase in postpartum depression cases is expected to drive the growth of the postpartum depression market. Postpartum depression refers to excessive worry and emotional distress that occurs after childbirth, often accompanied by physical symptoms. It is common for postpartum depression to coexist with postnatal depression and anxiety, with symptoms potentially starting at any point during the first year after birth. Treatment options for postpartum depression include psychotherapy, also known as talk therapy or mental health counseling, medications, or a combination of both, which contributes to the market's growth. For example, a survey of 1.1 million mothers conducted by the University of Virginia School of Medicine (UVA SoM) in February 2022, found that first-time mothers, those under 25, and mothers of twins were most at risk for postpartum depression. Among age groups, women aged 18-24 had the highest self-reported rate of postpartum depression symptoms at 10%. Mothers of twins had a higher rate of symptoms (11.3%) compared to those with single children (8.3%). As such, the rising incidence of postpartum depression will drive the growth of the postpartum depression market.

The growing number of childbirths is expected to accelerate the growth of the postpartum depression market. Childbirth is the process in which a baby is born from the mother's uterus, usually through the vaginal canal. The increase in childbirths contributes to the postpartum depression market, as this condition is a common mental health issue affecting women following delivery. Postpartum depression can lead to various symptoms, such as sadness, anxiety, fatigue, and difficulty bonding with the baby. For instance, a report published by the Centers for Disease Control and Prevention (CDC) in January 2023 indicated a 1% rise in registered births in the United States, reaching a total of 3,664,292 births compared to the previous year. Therefore, the rising number of childbirths is driving the expansion of the postpartum depression market.

Companies active in the postpartum depression market are focusing on innovation to maintain their market presence. The need for faster-acting therapies and innovative care delivery methods for postpartum depression has arisen due to the limited treatment options available. For example, in February 2023, Biogen Inc., a U.S.-based biotechnology company, and Sage Therapeutics Inc., a U.S.-based biopharmaceutical company, announced the acceptance of a new drug application (NDA) by the United States Food and Drug Administration (FDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an experimental medication being investigated as a 14-day, once-daily, fast-acting oral therapy for individuals with MDD and PPD. As a neuroactive steroid, zuranolone functions as a positive allosteric modulator of GABA-A receptors, offering a unique mechanism of action. It is designed to rapidly reset dysregulated neural networks to aid in restoring brain function and, in turn, influence the brain networks responsible for mood, arousal, behavior, and cognition.

In December 2022, Biogen Inc. and Sage Therapeutics Inc. joined forces for an undisclosed amount, aimed at the development and commercialization of drugs for major depressive disorder (MDD), postpartum depression (PPD), as well as other mental disorders, essential tremor, and various neurological conditions. Sage Therapeutics Inc. specializes in the development of therapies for neurological conditions such as depression, PPD, neurology, and neuropsychiatric disorders. This collaboration enhances the prospects for advancing treatments in the field of mental health and neurology.

Major companies operating in the postpartum depression market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol Myers Squibb Co., AstraZeneca PLC, GlaxoSmithKline LLC, Takeda Pharmaceutical Company, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Viatris Inc., Northwell Health, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Mallinckrodt Pharmaceuticals PLC, Sage Therapeutics Inc.

North America was the largest region in the postpartum depression market in 2024. The regions covered in postpartum depression report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the postpartum depression market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The postpartum depression market consists of revenues earned by entities by providing services such as medications, psychotherapy (cognitive behavioral therapy) and support group participation. The market value includes the value of related goods sold by the service provider or included within the service offering. The postpartum depression market also includes the sales of medications such as Selective serotonin reuptake inhibitors (SSRIs), Serotonin and norepinephrine reuptake inhibitors (SNRIs), Bupropion and Tricyclic antidepressants (TCAs). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Postpartum Depression Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on postpartum depression market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for postpartum depression ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The postpartum depression market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Postpartum Depression Market Characteristics

3. Postpartum Depression Market Trends And Strategies

4. Postpartum Depression Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Postpartum Depression Growth Analysis And Strategic Analysis Framework

6. Postpartum Depression Market Segmentation

7. Postpartum Depression Market Regional And Country Analysis

8. Asia-Pacific Postpartum Depression Market

9. China Postpartum Depression Market

10. India Postpartum Depression Market

11. Japan Postpartum Depression Market

12. Australia Postpartum Depression Market

13. Indonesia Postpartum Depression Market

14. South Korea Postpartum Depression Market

15. Western Europe Postpartum Depression Market

16. UK Postpartum Depression Market

17. Germany Postpartum Depression Market

18. France Postpartum Depression Market

19. Italy Postpartum Depression Market

20. Spain Postpartum Depression Market

21. Eastern Europe Postpartum Depression Market

22. Russia Postpartum Depression Market

23. North America Postpartum Depression Market

24. USA Postpartum Depression Market

25. Canada Postpartum Depression Market

26. South America Postpartum Depression Market

27. Brazil Postpartum Depression Market

28. Middle East Postpartum Depression Market

29. Africa Postpartum Depression Market

30. Postpartum Depression Market Competitive Landscape And Company Profiles

31. Postpartum Depression Market Other Major And Innovative Companies

32. Global Postpartum Depression Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Postpartum Depression Market

34. Recent Developments In The Postpartum Depression Market

35. Postpartum Depression Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기